103 hasil untuk "Steven Simoens"
Menampilkan 1–20 · 0,22 detik · RSS
-
Artikel Jurnal
How to assess the value of medicines?
This study aims to discuss approaches to assessing the value of medicines. Economic evaluation assesses value by means of the incremental cost-effectiveness ratio (ICER). Health is maximised by selecting medicines with increasing ICERs until the budget is exhausted. The budget size determines the…
-
Artikel Jurnal
Biosimilar medicines and cost-effectiveness
Steven SimoensResearch Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, BelgiumAbstract: Given that biosimilars are agents that are similar but not identical to the reference biopharmaceutical, this study aims to…
-
Artikel Jurnal Teks lengkap
Assessment of methodological quality of economic evaluations in belgian drug reimbursement applications.
OBJECTIVES: This paper aims to assess the methodological quality of economic evaluations included in Belgian reimbursement applications for Class 1 drugs. MATERIALS AND METHODS: For 19 reimbursement applications submitted during 2011 and Spring 2012, a descriptive analysis assessed the…
Juga tersedia di: PLOS
-
Artikel Jurnal
Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies
BackgroundIn an era of scarce resources, policy makers, neurologists and other stakeholders need to be aware of the economic burden of multiple sclerosis and the cost-effectiveness of disease-modifying therapies. The aim of this article is to provide a mini-review of these health economic facets of…
-
Artikel Jurnal Teks lengkap
Health Economics of Antibiotics
Antibiotics have made a significant contribution to improving patient health, but policy makers and health care payers are concerned about the costs of antibiotics in addition to their effectiveness. This paper aims to assess the value of antibiotics by examining incremental cost-utility ratios of…
-
Artikel Jurnal Teks lengkap
Generic Medicine Pricing Policies in Europe: Current Status and Impact
Generic medicine pricing is an area of national responsibility of European Union countries. This article aims to present the current status and impact of generic medicine pricing policies in ambulatory care in Europe. The study conducts a literature review of policies relating to free-pricing…
-
Artikel Jurnal Teks lengkap
Emerging Insights into European Markets of Biologics, Including Biosimilars
Biological medicinal products have revolutionised the treatment of many diseases, e [...]
-
Artikel Jurnal
R&D Costs of New Medicines: A Landscape Analysis
Over the years, questions have been raised over R&D costs of new medicines. The aim of this study is to conduct a landscape review of the (drivers of) R&D costs of a new medicine derived from the peer-reviewed and grey literature. Included studies have drawn data either from confidential company…
-
Artikel Jurnal
Tendering and biosimilars: what role for value-added services?
Background: Access to biologic medicines (including biosimilars) across Europe is largely governed by a process of tendering conducted by health authorities. Over-reliance on treatment costs in awarding tenders has the potential to hinder competition and undermine the long-term sustainability of…
-
Artikel Jurnal
Guidance for Demonstrating the Societal Value of new Antibiotics
Given that antibiotic use is associated with externalities, standard economic evaluation which considers costs and health gains accruing to patients under-values antibiotics. Informed by a scoping review, this discussion paper aims to identify the societal value elements of antibiotics and to…
-
Artikel Jurnal
Off-label use of orphan medicinal products: a Belgian qualitative study
Abstract Background Off-label use of (orphan) medicinal products for (rare) diseases is quite common but not underpinned by clinical studies to confirm efficacy and safety. No risk-analyses by regulatory agencies are carried out. The objective of this study was to map off-label use of orphan…
-
Artikel Jurnal Teks lengkap
Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
This study aimed to compare drug costs and healthcare costs of a 1 year adjuvant course with intravenous biosimilar trastuzumab vs. subcutaneous reference trastuzumab in HER2-positive breast cancer from the Belgian hospital perspective. Our simulation is based on the methodology used by Tjalma and…
-
Artikel Jurnal
What role for real-world evidence in market access of biosimilars?
Experience with the use of biosimilars in real-life practice provides an excellent opportunity to collect real-world evidence aimed at addressing residual uncertainties about biosimilars. Hence, this Perspective aims to explore the role of real-world evidence on biosimilars by showcasing how…
-
Artikel Jurnal
Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review
Objectives: This research aims to evaluate the methodological quality of budget impact analyses for orphan drugs and to provide suggestions for future analyses.Methods: Conference abstracts and peer-reviewed literature on budget impact analyses were collected through searches of Pubmed and Embase…
-
Artikel Jurnal Teks lengkap
Insights into European drug shortages: a survey of hospital pharmacists.
Drug shortages are a complex and global phenomenon. When a drug cannot be delivered at the moment of patient demand, every stakeholder in the health care system is affected. The aim of this study was to investigate the characteristics, clinical impact, financial impact and management of drug…
Juga tersedia di: PLOS
-
Artikel Jurnal
How to Value Orphan Drugs? A Review of European Value Assessment Frameworks
Background: Decision-makers have implemented a variety of value assessment frameworks (VAFs) for orphan drugs in European jurisdictions, which has contributed to variations in access for rare disease patients. This review provides an overview of the strengths and limitations of VAFs for the…
-
Artikel Jurnal
A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe
Objectives: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, Kalydeco® (ivacaftor), Orkambi® (lumacaftor/ivacaftor) and Symkevi® (tezacaftor/ivacaftor), have substantially improved patients’ lives yet significantly burden healthcare budgets. This analysis aims to compare…